person · Reporting owner
Del Giudice Matthew Paul
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director | June 12, 2026 | June 15, 2026 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director | April 16, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2036-06-12 | Direct | 50,000 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 50,000 · Balance 50,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. F2: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.
F2: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
F3: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.
Telomir Pharmaceuticals, Inc.
Report date April 16, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2036-04-16 | Direct | 50,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 50,000 · Balance 50,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026. F2: The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
F2: The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001493152-26-028712 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-12 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3 · balance_after: Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | Disposition to issuerIncentive Stock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001493152-26-025113 · ownership.xml · derivative · entry 2 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2034-08-27 F2 · price: The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:00 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001493152-26-025113 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-05-21 F2 · price: The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The options are fully exercisable. F2 · balance_after: The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price. Read SEC document |
| April 16, 2026 Filed Jul 27, 2026 20:30 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001493152-26-034812 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-04-16 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. F2 · balance_after: The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 22:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001493152-24-049504 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2034-12-09 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3 · balance_after: Represents 25,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001493152-24-034369 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-08-27 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. F2 · balance_after: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:53 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantNonqualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001493152-24-011570 · ownership.xml · derivative · entry 1 Del Giudice Matthew Paul · CIK 0002016630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-25 F1 · derivative.exercise_date: The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.